We have previously demonstrated that the responsiveness of multiple myeloma (MM) cells to interferon-alpha (IFN-a) stimulation is variable, with an atypical growth response displayed by some cells. Here we report the ability of IFN-a to induce tyrosine phosphorylation of a 180 kDa band in the KAS-6/1 MM cell line, which is growth responsive to IFN-a. Further characterization demonstrated that this band corresponds to ErbB3. To our knowledge, this is the first report of ErbB3 expression in a cell type of the hematopoietic lineage. Although ErbB receptors have been shown to crosscommunicate with various other receptors, our results show for the first time that the IFN-a receptor can crosscommunicate with ErbB3. To address the significance of these observations, we transfected ErbB3-negative DP-6 MM cells with ErbB3 and used siRNA to silence ErbB3 in the KAS-6/1 cell line. Although IFN-a transactivated ErbB3 in the DP-6 transfectants, it did not confer growth responsiveness to IFN-a. Interestingly, silencing ErbB3 expression in the KAS-6/1 cells decreased the overall growth response to IFN-a and to interleukin-6. These results suggest that ErbB3 expression alone does not uniquely confer IFN-a growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor.
Introduction
Multiple myeloma (MM) is a typically fatal plasma cell malignancy, which accounts for 1% of all malignancies and B12% of all hematological malignancies. A hallmark feature of MM is the striking heterogeneity that is observed in clinical disease. A variety of biologic and molecular factors, including altered tumor cell growth factor responsiveness and receptor expression, likely account for this heterogeneity and the accompanying challenge in treating this disease. An added biological challenge is introduced by the ability of some receptors to act in a nonlinear fashion and transactivate unrelated receptors, thereby perhaps providing an attractive mechanism by which tumor cell growth factor/cytokine responses can be amplified (reviewed by Hill, 1998) . Given that tumor cells, including myeloma cells, often acquire atypical expression of one or more signaling receptors during malignant transformation (reviewed in Bregman and Sipes, 1986) , from a therapeutic standpoint, it becomes imperative to understand fully the nonlinear signaling in myeloma cells.
At the present time, there is no curative treatment for multiple myeloma. However, several chemotherapeutic agents have been found to induce temporary remission for most patients and once remission is achieved, maintenance therapy agents such as interferon-alpha (IFN-a) have been used to increase the remission plateau phase (Salmon et al., 1991) . Typically, IFN-a mediates antiproliferative, antiviral, immunomodulatory, and antitumor activities (reviewed in Pestka, 1997) . However, there are a number of reports demonstrating that IFN-a can exacerbate myeloma disease course in vivo in some patients (Blade et al., 1991 , Sawamura et al., 1992 . In addition, we and others have demonstrated that in vitro myeloma cell line responses to IFN-a can be variable, with growth stimulation observed under some circumstances (Brenning et al., 1985; Jourdan et al., 1991; Westendorf et al., 1996; Jelinek et al., 1997) . Furthermore, we have also previously reported that stimulation with IFN-a can differentially activate certain signaling pathways in MM cells. For example, IFN-a stimulation of the KAS-6/1 cell line resulted in an atypical proliferative response accompanied by striking activation of the activated MAP kinase (MAPK) pathway, whereas no MAPK activation was seen in the ANBL-6 cell line, which is growth suppressed by IFN-a (Arora et al., 1999) . Therefore, the variable myeloma cell IFN-a responsiveness represents an excellent example of the disease heterogeneity discussed above. During the course of our studies investigating the mechanism(s) of variable IFN-a responses in myeloma, we serendipitously and unexpectedly discovered that the IFN-a growth responsive KAS-6/1 MM cell line expresses ErbB3, whereas MM cell lines that are growth arrested by IFN-a do not.
ErbB3 is a member of the ErbB family of receptor tyrosine kinases, whose additional members include the epidermal growth factor receptor (EGFR) or ErbB1, ErbB2, and ErbB4. Of note, the ErbB receptor family members are typically involved in cellular proliferation and differentiation responses, but are typically not expressed in hematopoietic lineage cells (Kraus et al., 1989) . In addition, ErbB3 is the only member of this receptor family that does not display intrinsic kinase activity and thus, ErbB3 must heterodimerize with another ErbB family member in order to initiate signal transduction (reviewed in Olayioye et al., 2000) . Relevant to the current studies, a variety of reports have demonstrated that the ErbB family of receptors can participate in non-ErbB receptor crosstalk or can become subsequently activated through the stimulation of unrelated receptor subtypes. For example, Yamauchi et al. (1997) demonstrated that stimulation of rat hepatocytes with growth hormone (GH) not only resulted in phosphorylation of the GH receptor (GHR), but also resulted in tyrosine phosphorylation of the EGFR. This crosstalk was shown to be facilitated by Jak2 and was demonstrated to be essential for GHinduced MAP kinase activation.
Owing to the growing awareness of unexpected receptor interactions, particularly in transformed cells, and the ability of transactivated receptors to impact the downstream cellular consequences of growth factors or cytokines, our goal in this study was to determine whether atypical ErbB3 expression in the KAS-6/1 cell line explained the atypical IFN-a growth response. Our results show for the first time, ErbB3 expression in a hematopoietic cell line, and demonstrate the unique ability of the IFN-a receptor to crosscommunicate with ErbB3. Furthermore, we investigated whether this unique receptor interaction modulated myeloma cell IFN-a proliferative responses.
Results

IFN-a induces tyrosine phosphorylation of a 180 KDa protein in KAS-6/1 cells
In this study, our goal was to address the possibility that signal transduction pathways diverge in myeloma cells that display an atypical growth response to stimulation with IFN-a. Thus, we have previously reported that the interleukin (IL-6)-dependent KAS-6/1 myeloma cell line grows in response to IFN-a, whereas other IL-6-dependent myeloma cell lines, such as ANBL-6, DP-6, and KP-6, are growth arrested by IFN-a (Westendorf et al., 1996; Jelinek et al., 1997) . In our initial experiments, the KAS-6/1 and ANBL-6 cell lines were stimulated with IL-6 and IFN-a for 10 min, and the global patterns of tyrosine phosphorylation were studied ( Figure 1a) . We observed an increase in tyrosine phosphorylation of several proteins following stimulation with both IL-6 and IFN-a. Of note, IFN-a stimulation resulted in the striking appearance of a tyrosine-phosphorylated protein with an approximate molecular weight of 180 kDa in the KAS-6/1 cell line, but not in the ANBL-6 cell line.
Myeloma cell expression of ErbB family members
During the course of our studies on myeloma cell growth control (French et al., 2002) , we serendipitously discovered that the KAS-6/1 cell line expressed mRNA for ErbB3. ErbB3, as well as the other three members of the ErbB receptor family have molecular weights in the range of 170-190 kDa. Given the increasing role that ErbB receptors play in several cancers, including breast and prostate, we next examined the cell surface expression of ErbB family members. The KAS-6/1 cell line exhibited high levels of ErbB3 expression in the apparent absence of ErbB1, ErbB2, and ErbB4, whereas the ANBL-6 cell line did not express ErbB receptors (Figure 1b) . In results not shown, we also failed to detect, by fluorescence-activated cell sorting (FACS), ErbB3 or any other ErbB family members on three other myeloma cell lines (DP-6, KP-6, MC-Q), which are also growth suppressed by IFN-a. Since myeloma cells may express ErbB receptors at a level undetectable by flow cytometry, we next examined ErbB1-4 mRNA expression by reverse transcriptase-polymerase chain reaction (RT-PCR). As shown in Figure 1c , ErbB3 mRNA was detected by RT-PCR in the KAS-6/1 cell line, while mRNA for any other member of the ErbB family was not detected. These results confirm our flow cytometric analysis. Similarly, no expression of ErbB family members was detected at the mRNA level in the ANBL-6, DP-6, KP-6, and MC-Q MM cell lines.
IFN-a induces tyrosine phosphorylation of ErbB3
Since the molecular weight of ErbB3 is similar to the size of the 180 kDa protein that became phosphorylated following IFN-a stimulation in KAS-6/1, but not ANBL-6 cells, we next wished to determine if ErbB3 becomes tyrosine phosphorylated following IFN-a stimulation. To address this question, KAS-6/1 and ANBL-6 cells were stimulated with IFN-a, ErbB3 was immunoprecipitated, and activation was assessed by ErbB3 tyrosine phosphorylation status. Indeed, IFN-a stimulated the tyrosine phosphorylation of ErbB3 in the KAS-6/1 cells ( Figure 2a ). As expected, ErbB3 was not immunoprecipitated from the ANBL-6 cell line. These data support the conclusion that the 180 kDa protein in the KAS-6/1 cells is ErbB3 and that it becomes activated following stimulation with IFN-a.
The kinetics of IFN-a-induced tyrosine phosphorylation of ErbB3 parallel the kinetics of IFN-aR activation To better understand the mechanism(s) underlying IFNa-induced activation of ErbB3, we next examined and compared the activation kinetics of both IFN-aR and ErbB3, following stimulation with IFN-a. Figure 2b demonstrates that IFN-a stimulation for as short as 1 min resulted in the tyrosine phosphorylation of both ErbB3 and IFn-a receptor crosstalk in myeloma cells DK Walters et al the IFN-aR1 and ErbB3 in KAS-6/1 cells, and both receptors remained phosphorylated for at least 15 min before slowly declining back to basal levels. Based on the rapid kinetics of IFN-a-induced tyrosine phosphorylation of ErbB3 and because IFN-a is not a known ligand for ErbB3, we conclude that ligand-induced activation of the IFN-a receptor transactivates ErbB3.
IFN-a-induced tyrosine phosphorylation of ErbB3 is specific
To determine the specificity of IFN-a-induced phosphorylation of ErbB3, we next examined the phosphor- induce tyrosine phosphorylation of ErbB3. However, upon darker exposure, IL-6 was observed to induce a very slight increase in ErbB3 phosphorylation (results not shown). Finally, EGF and HRG-b1 failed to stimulate tyrosine phosphorylation of ErbB3, and thus provide further evidence that the KAS-6/1 cells fail to express a kinase-proficient member of the ErbB family.
The IFN-aR and ErbB3 do not form a detectable physical complex
To determine if the IFN-aR and ErbB3 physically interact, we next examined whether ErbB3 could be coimmunoprecipitated with the IFN-aR and vice versa following IFN-a stimulation. However, we failed to find evidence by immunoprecipitation methods that ErbB3 could associate with the IFN-aR in the presence or absence of IFN-a stimulation (Figure 4) . Instead, these results suggest that the crosstalk occurring between these receptors must occur through a mechanism, which is yet to be identified.
IFN-a induced tyrosine phosphorylation of ectopically expressed ErbB3
We next wished to determine if the crosstalk between the IFN-a receptor and ErbB3 in KAS-6/1 cells was a unique feature of this cell line. To address this question, we examined whether IFN-a receptor/ErbB3 crosstalk could be reconstituted in an ErbB3-negative myeloma cell line. Thus, two ErbB3-negative, IFN-aR-positive MM cell lines, DP-6 and KP-6, were transfected with an hErbB3 expression vector. Figure 5a illustrates the flow cytometry histogram profiles of the DP-6 and KP-6 transfectants. The ErbB3 transfectants, empty vector transfectants, and KAS-6/1 cells were then stimulated with IFN-a and the phosphorylation status of ErbB3 was assessed. As shown in Figure 5b , ErbB3 became tyrosine phosphorylated in both the DP-6 and KP-6 ErbB3 transfectants following IFN-a stimulation. These data indicate that IFN-a-induced tyrosine phosphorylation of ErbB3 does not uniquely occur in the KAS-6/1 cell line and that this novel phenomenon can be reconstituted in previously ErbB3-negative myeloma cell lines. ErbB3 and IFn-a receptor crosstalk in myeloma cells DK Walters et al
Ectopic ErbB3 expression does not confer IFN-a growth responsiveness
Given that the KAS-6/1 cell line displays an atypical growth response to IFN-a stimulation, it is possible that anomalous ErbB3 expression in this cell line underlies this response. To address this possibility, we next assessed the ability of the DP-6 ErbB3 transfectants to display an increase in DNA synthesis, following stimulation with IFN-a. Figure 6 displays the mean proliferative response observed in four independent experiments and it could be seen that exogenous expression of ErbB3 in the DP-6 cell line did not facilitate a significant proliferative response following IFN-a stimulation. Similar results were seen with the KP-6 transfectants (results not shown). ErbB3 and IFn-a receptor crosstalk in myeloma cells DK Walters et al (Walters and Jelinek, 2002) . The ability of the siRNAtransfected cells to proliferate in response to IFN-a was then assessed by 3 H-Tdr incorporation. The ErbB3-specific siRNA transfectants showed a striking, overall decrease in the magnitude of IL-6-and IFN-a-stimulated 3 H-Tdr incorporation as compared to the controlscrambled transfectants and the wild-type control cells (Figure 7b ). Despite the decrease in overall proliferation, no significant difference in the viability of these cells was observed when assessed by annexin/PI staining (data not shown). However, transfection of the ErbB3-specific siRNA or the scrambled siRNA into ErbB3-negative DP-6 cells was without effect (data not shown). These data indicate that silencing of ErbB3 in the KAS-6/1 cell line significantly reduces the ability of these cells to demonstrate a normal proliferative response to IL-6 or IFN-a.
RNAi-induced downregulation of ErbB3 does not influence the IFN-a-induced activation of MAPK or Stat3 in the KAS-6/1 cell line
We have previously demonstrated that the MAPK pathway becomes activated in KAS-6/1 cells following stimulation with IFN-a, but not in ANBL-6 cells (Arora et al., 1999) , and that blockade of the MAPK pathway completely blocked IFN-a-stimulated proliferation of the KAS-6/1 cells. After taking these data into consideration and the fact that ErbB3 can activate members of the MAPK pathway (Soltoff et al., 1994; Fiddes et al., 1998) , we hypothesized that ErbB3 may contribute to the activation of the MAPK pathway in KAS-6/1 cells, and that silencing of ErbB3 via RNAi would thus impair proliferative responses to IL-6 and IFN-a, as discussed above. In order to test this hypothesis, we transfected the KAS-6/1 cells with either the scrambled siRNA duplex or the ErbB3-specific siRNA duplex and tested the ability of the cells to activate MAPK following IFN-a stimulation. However, downregulation of ErbB3, which was confirmed by flow cytometry and Western blot (results not shown), did not significantly affect IFN-a-stimulated MAPK activation (Figure 8) . Similarly, downregulation of ErbB3 had no effect on Stat-3 activation, which is also activated following IL-6 and IFN-a stimulation. These data suggest that ErbB3 transactivation does not play a significant role in the activation of MAPK, and that its contribution to the proliferative response of the KAS-6/1 
Discussion
In the current study, we report two novel observations. First, this is the first demonstration of ErbB3 expression in hematopoietic lineage cells. Second, we report the novel ability of IFN-a to transactivate ErbB3. With respect to the first point, previous studies using Northern blot and immunohistochemical analyses of normal adult human tissues have demonstrated that ErbB3 is normally expressed in the skin, stomach, lung, kidney, brain, and placenta. By contrast, ErbB3 expression has not been detected in normal fibroblasts, skeletal muscle, or lymphoid cells (Kraus et al., 1989) . ErbB3 is also expressed in several human mammary cancer cell lines (Lemoine et al., 1992) ; however, on its own, ErbB3 was not transforming, even when overexpressed. By contrast, ErbB3 overexpression is transforming in the presence of ErbB2 (Alimandi et al., 1995) . Consequently, ErbB3 has been suggested to play a role in tumorigenesis or tumor progression.
Here we demonstrate that the myeloma cell line KAS-6/1 expresses ErbB3, in the absence of other ErbB members. Because of this and because ErbB3 is not active without heterodimerization with an ErbB kinase proficient partner, we did not expect ErbB3 to be active in the KAS-6/1 cell line. However, we made the surprising observation that crosscommunication occurs between the IFN-a receptor and ErbB3 following stimulation with IFN-a. This was an unanticipated result because IFN-a is not known to be a ligand for ErbB3 and to our knowledge, crosstalk between these two receptors has yet to be reported. However, there is precedence in the literature for crosscommunication between ErbB family members and distinctly unrelated membrane receptors. For example, Qiu et al. (1998) demonstrated that in prostate carcinoma cells, IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, and that the signaling component of the IL-6R, gp130, actually forms a complex with ErbB2 in an IL-6-dependent manner. Importantly, this association was shown to be required for IL-6-induced MAP-kinase activation. Our results, however, can be distinguished from other studies in that we report the ability of a member of the cytokine receptor superfamily to crosstalk with ErbB3 in the absence of expression of kinaseproficient ErbB receptors and without the apparent formation of a physical receptor association. However, more rigorous techniques may be required to detect lowlevel complex formation, for example, use of crosslinking reagents.
As the KAS-6/1 cells display an atypical growth response to IFN-a, it was possible that ErbB3 was playing a pivotal role in this response. However, two lines of investigation suggest that the role of ErbB3 in the KAS-6/1 cells is complex. First, a proliferative response to IFN-a stimulation was not observed when ErbB3 was exogenously expressed in previously ErbB3-negative MM cell lines, despite the presence of IFN-ainduced tyrosine phosphorylation of ErbB3 in these cells. Second, we employed siRNA to downregulate ErbB3 in the KAS-6/1 cell line and then examined whether the atypical mitogenic response to IFN-a was extinguished. Interestingly, the overall responsiveness of the KAS-6/1 cell line to IFN-a was significantly reduced following the downregulation of ErbB3; however, it was not completely extinguished. However, very low levels of ErbB3 expression remain even following siRNAmediated downregulation, and thus it remains possible that these low levels are sufficient to promote the atypical growth of the KAS-6/1 cells to IFN-a. In addition, the overall responsiveness of the cells to IL-6 was also significantly reduced, although no difference in cell viability could be detected following ErbB3 downregulation. Consequently, these data suggest that ErbB3 may also play a role in the IL-6 proliferative response of the KAS-6/1 cell line.
Interpretation of the effects of ErbB3 silencing in the KAS-6/1 cells is similarly complex. Thus, the downregulation of ErbB3 resulted in an overall decrease in KAS-6/1 cell responsiveness to both IFN-a and IL-6. Despite this complexity, this was an intriguing result because IL-6 stimulation of the KAS-6/1 cell line also induced very low levels of tyrosine phosphorylation of ErbB3 (results not shown). Collectively, these data suggest that even low-level transactivation of ErbB3 may be sufficient for it to play a role in the proliferation of this cell line. ErbB3 may therefore play a scaffolding role in this cell line that facilitates activation of signaling pathways that are common to, or are required for inducing proliferative responses to IL-6 and the atypical proliferative response to IFN-a. Interestingly, ErbB members have previously been shown to perform scaffolding-like roles in other cell types. For example, Yamauchi et al. (1997) demonstrated that in rat hepatocytes, growth-hormone-induced activation of the MAPK pathway required the EGFR but did not require activation of EGFR intrinsic kinase activity. In the current report, we investigated whether ErbB3 played a similar scaffolding role required for IFN-ainduced activation of MAPK in the KAS-6/1 cells. However, when ErbB3 was downregulated by siRNA, ErbB3 and IFn-a receptor crosstalk in myeloma cells DK Walters et al no alteration in IFN-a-induced activation of MAPK was observed in the KAS-6/1 cell line suggesting that ErbB3 is not primarily responsible for IFN-a-induced activation of MAPK. Nevertheless, it remains possible that ErbB3 allows for the activation of an alternative pathway that is responsible for the mitogenic responses to IFN-a and IL-6. It is interesting to consider that ErbB3 has 13 tyrosine residues in its cytoplasmic domain, and that phosphorylation of specific tyrosine residues creates docking sites for Shc, Grb7, and the p85 subunit of PI3-kinase (Soltoff et al., 1994 , Fiddes et al., 1998 . In addition, under certain circumstances, such as in the absence of ligand, it has been shown that alternative pathways can become activated. Indeed, McManus et al. (2000) found that constitutively activated v-erb induced the formation of a complex involving myosin II. This complex was subsequently shown to be a transforming-specific signaling module. Their findings further suggest that ligand-independent molecules may transduce oncogenic signals, which are distinct from ligand-dependent signals. A similar situation may exist in the KAS-6/1 cells such that even lowlevel tyrosine phosphorylation of ErbB in the absence of an ErbB ligand (i.e., via nonlinear signaling from components of the IFN-a receptor signaling complex or IL-6 signaling complex) may result in distinct downstream signaling events. The specific signaling cascades activated via IFN-a-induced tyrosine phosphorylation of ErbB3 are currently under investigation.
In conclusion, our results contribute to the growing body of literature concerning the ability of distinct cell surface receptors to act in a nonlinear fashion or crosscommunicate, facilitating the diversification of downstream signals and perhaps cell phenotype and/or function. We believe that novel receptor interactions have the potential to allow dysregulated tumor cell function. In this regard, atypical expression of ErbB3 in multiple myeloma may provide a mechanism whereby the tumor cell is afforded with either an ability to grow or to survive. We are currently investigating this possibility, along with analysing primary myeloma cells for ErbB3 expression. Finally, it remains possible that this crosstalk phenomenon is a result of aberrant expression of ErbB3 in a cell of the hematopoietic lineage, and that this phenomenon will not occur if other ErbB members are concurrently expressed.
Materials and methods
Cell lines, culture medium and reagents
The myeloma cell lines ANBL-6, DP-6, KAS-6/1, KP-6, and MC-Q were derived from primary patient myeloma cells and all have been described previously with the exception of MC-Q (Westendorf et al., 1996; Jelinek et al., 1997) . These cell lines were maintained as previously described (Arora et al., 1999) . The breast adenocarcinoma cell lines MCF-7 and SKBR-3 were purchased from ATCC. These cell lines were maintained in DMEM supplemented with 10% FCS, 100 U/ml penicillin G, 50 mg/ml gentamicin, 100 mg/ml streptomycin, and 2 mmol/ l glutamine. Recombinant purified IFN-a2b (Schering, Kenilworth, NJ, USA) was used at 10 000 U/ml in immunoprecipitation experiments and at 1000 U/ml in DNA synthesis assays. IL-6 (Novartis Pharma, Basel, Switzerland) was used at 50 ng/ml in immunoprecipitation experiments and 1 ng/ml in DNA synthesis assays, EGF (Biosource, Camarillo, CA, USA) was used at 100 ng/ml, heregulin beta-1 (HRG-b1; Lab Vision, Fremont, CA, USA) was used at 150 ng/ml, erythropoietin (EPO; Amgen Inc., Raritan, NJ, USA) was used at 100 U/ml, IGF-1 (Peninsula Laboratories Inc., Belmont, CA, USA) was used at 200 ng/ml, IFN-b (Calbiochem, San Diego, CA, USA) was used at 10 000 U/ml, and IFN-g (Pepro Tech Inc., Rocky Hill, NJ, USA) was used at 10 000 U/ml. ErbB3 transfectants were selected and maintained in 250 mg/ml G418 (Calbiochem).
Reverse transcriptase-polymerase chain reaction RT-PCR analysis
Total RNA was isolated using TRIzol (Life Technologies, Gibco BRL) and reverse transcribed using the First-Strand cDNA Synthesis Kit (Amersham, Piscataway, NJ, USA). PCR was carried out in the presence of HotStarTaq Master Mix (Qiagen; 1.5 mm MgCl 2 , 0.8 mm dNTPs, HotStarTaq DNA polymerase), 1 mm of ErbB1, ErbB2, ErbB3, ErbB4 (ErbB primers are as described in Wainstein et al., 1994) , or b-actinspecific oligonucleotides (b-actin 5 0 GACTTCGAGCAAGA-GATGGCCAC; b-actin 3 0 GTTACGGTCCCATGTACCA-CCAC). Amplification of cDNA was performed for 30 cycles with a profile of 951C for 50 s, 601C for 2 min, 721C for 2 min. PCR products were electrophoresed in a 1.5% agarose gel containing ethidium bromide and photographed. Molecular weight markers consisted of both lDNA/HindIII RF and jX174 DNA/HaeIII RF (Promega, Madison, WI, USA). The expected sizes of the ErbB1-4 and b-actin PCR products are 726, 821, 1129, 1013 and 486 bp, respectively.
Immunofluorescence analysis
Analysis of cell surface protein expression was determined by immunofluorescence. Briefly, 1 Â 10 6 cells were incubated with monoclonal antibodies (mAbs) to the IFN-a receptor (Research Diagnostics Inc., Flanders, NY, USA), ErbB2, ErbB3, or ErbB4 (all obtained from Neomarkers, Fremont, CA, USA) for 30 min on ice in PBS/2% FCS, washed and then incubated with PE-conjugated goat anti-mouse IgG for 30 min (Biosource, Camarillo, CA, USA). ErbB1 expression was assessed using a PE-conjugated mouse anti-human ErbB1 (Pharmingen, San Diego, CA, USA) mAb for 30 min. Cells were then washed, fixed in 1% paraformaldehyde and analysed for immunofluorescence on a FACSCAN flow cytometer (Becton Dickinson, Mountain View, CA, USA). Control Abs included mouse IgG1, IgG2a, and PE-conjugated IgG2bk. Data were analysed using WinMDI 2.5 software.
Immunoprecipitation and immunoblotting
Cells were cultured in IL-6-free medium supplemented with 0.5% BSA prior to IFN-a addition. Cells (1.0-2.0 Â 10 7 ) were lysed using RIPA lysis buffer (50 mm Tris pH 7.4, 150 mm NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 1 mm EDTA, 15 mm sodium molybdate, 1 mm NaF) or Brij lysis buffer (50 mm Tris pH 7.6, 150 mm NaCl, 10 mm NaF, 1% Brij-97) supplemented with protease inhibitors (10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml pepstatin, 2 mm Na 3 VO 4 , and 1 mm PMSF). Lysates were cleared of insoluble material by centrifugation for 10 min at 14 000 r.p.m. Following
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